<DOC>
	<DOCNO>NCT00585533</DOCNO>
	<brief_summary>This study evaluate Tarceva select population patient untreated advance non-small cell lung cancer anticipate relatively good ( indolent ) prognosis base clinical criterion . It anticipate selection enrich tumor characteristic likely benefit EGFR inhibitor treatment ( survival great 90 day ) . The goal strategy provide less toxic , oral treatment patient advance NSCLC interfere patient receive chemotherapy point future may prolong time chemotherapy relate progression . Patients remain study disease progress , decline performance status , patient tolerate side effect develop symptom require conventional chemotherapy .</brief_summary>
	<brief_title>A Phase 2 Study Tarceva Untreated , Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Primary Objective To determine Time Chemotherapy Progression ( ie include time Tarceva monotherapy chemotherapy ) advance NSCLC Secondary Objectives To evaluate survival response rate associate Tarceva treatment To study frequency symptom improvement ( Lung Cancer Subscale )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Performance status 01 . Weight Loss &lt; 10 % precede 3 month Age 18 year old . Adjuvant chemotherapy allow &gt; 6 month protocol entry Adequate Organ Function Liver enzymes &lt; 2X normal , bilirubin = normal Oxygen saturation &gt; 89 % room air unless chronically oxygen dependent ( cancer relate ) Creatinine &lt; 2.0 mg Not pregnant lactating . No Clinical Brain Metastases No prior chemotherapy systemic disease Imminent need chemotherapy impend organ dysfunction allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>